JPWO2023249106A1 - - Google Patents
Info
- Publication number
- JPWO2023249106A1 JPWO2023249106A1 JP2023539099A JP2023539099A JPWO2023249106A1 JP WO2023249106 A1 JPWO2023249106 A1 JP WO2023249106A1 JP 2023539099 A JP2023539099 A JP 2023539099A JP 2023539099 A JP2023539099 A JP 2023539099A JP WO2023249106 A1 JPWO2023249106 A1 JP WO2023249106A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022101476 | 2022-06-24 | ||
| PCT/JP2023/023264 WO2023249106A1 (ja) | 2022-06-24 | 2023-06-23 | 筋萎縮性側索硬化症の治療剤又は予防剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2023249106A1 true JPWO2023249106A1 (https=) | 2023-12-28 |
Family
ID=89380133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539099A Pending JPWO2023249106A1 (https=) | 2022-06-24 | 2023-06-23 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260083723A1 (https=) |
| EP (1) | EP4545079A1 (https=) |
| JP (1) | JPWO2023249106A1 (https=) |
| KR (1) | KR20250026152A (https=) |
| CN (1) | CN119403554A (https=) |
| AU (1) | AU2023286251A1 (https=) |
| CA (1) | CA3256001A1 (https=) |
| WO (1) | WO2023249106A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801593A (en) | 1979-09-13 | 1989-01-31 | Burroughs Wellcome Co. | Chemotherapeutic agents |
| JP3209568B2 (ja) | 1991-04-16 | 2001-09-17 | 杏林製薬株式会社 | 新規環状アミノフェニル酢酸誘導体、その製造法及びそれらを有効成分とする免疫応答の修飾剤 |
| KR100236910B1 (ko) | 1992-12-14 | 2000-04-01 | 김영환 | 고집적 반도체 기억소자의 메모리셀어레이 제조방법 |
| DE10236910A1 (de) | 2002-08-12 | 2004-03-11 | Grünenthal GmbH | Substituierte 1,2,3,4-Tetrahydrochinolinderivate |
| ATE507220T1 (de) | 2003-12-20 | 2011-05-15 | Merck Patent Gmbh | Tetrahydropyranochinolinderivate |
| DE102005027170A1 (de) | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
| EP2733138B1 (en) * | 2011-07-15 | 2016-09-28 | Hamari Chemicals, Ltd. | Method for producing optically active tetrahydroquinoline |
| US20140228420A1 (en) | 2011-09-05 | 2014-08-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof |
| WO2019106434A1 (en) * | 2017-12-01 | 2019-06-06 | Collaborative Medicinal Development Pty. Ltd. | Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders |
| CN113631535B (zh) * | 2019-03-11 | 2024-04-12 | 协同医药发展有限公司 | 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物 |
| CN110372614B (zh) | 2019-07-03 | 2020-09-29 | 山东师范大学 | 一种四氢喹喔啉类化合物及制备方法与应用 |
| CN110464727B (zh) | 2019-09-06 | 2025-09-23 | 山东师范大学 | 3,4-二氢-2h-苯并-[1,4]恶嗪类药物或其盐在制备抑制铁死亡药物中的应用 |
| IL303307A (en) * | 2020-12-25 | 2023-07-01 | Toray Industries | Tetrahydroquinoline derivative and its medical use |
-
2023
- 2023-06-23 JP JP2023539099A patent/JPWO2023249106A1/ja active Pending
- 2023-06-23 CA CA3256001A patent/CA3256001A1/en active Pending
- 2023-06-23 EP EP23827288.4A patent/EP4545079A1/en active Pending
- 2023-06-23 US US18/877,122 patent/US20260083723A1/en active Pending
- 2023-06-23 AU AU2023286251A patent/AU2023286251A1/en active Pending
- 2023-06-23 WO PCT/JP2023/023264 patent/WO2023249106A1/ja not_active Ceased
- 2023-06-23 KR KR1020247034823A patent/KR20250026152A/ko active Pending
- 2023-06-23 CN CN202380048404.5A patent/CN119403554A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023249106A1 (ja) | 2023-12-28 |
| EP4545079A1 (en) | 2025-04-30 |
| AU2023286251A1 (en) | 2024-12-05 |
| US20260083723A1 (en) | 2026-03-26 |
| CN119403554A (zh) | 2025-02-07 |
| CA3256001A1 (en) | 2025-03-18 |
| KR20250026152A (ko) | 2025-02-25 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260313 |